The Cardiovascular Impact of COVID-19

Questions discussed:

- What have we learned and what can we expect?

- Clinical Impact – what is happening with clinical trials and product approvals?

- Impact of COVID on the Medtech Ecosystem

These questions were addressed by distinguished panel:

Dr. Michael R. Jaff (Moderator) is globally recognized as an expert on vascular medicine, having led multiple clinical trials and founded VasCore, the largest international vascular device imaging core lab in the field. He is Chief Medical Officer and VP of Peripheral Interventions at a global medical device company. Dr. Jaff is the past President of the Society for Vascular Medicine, the first incumbent of the Paul & Phyllis Fireman Endowed Chair in Vascular Medicine at the Massachusetts General Hospital, and Professor of Medicine at Harvard Medical School (leave of absence).

Dr. Louis Cannon is a Founder, Senior Managing Director at BioStar Capital, a successful physician-founded medical device venture fund and accelerator. Dr. Cannon, a former Judith Volkman Scholar in Residence, is the President of the Cardiac and Vascular Research Center of Northern Michigan. He has served as national & international Principal Investigator for landmark cardiovascular studies and has been repeatedly honored as one of "America’s Top Interventional Cardiologists.”

Justin Klein, MD, JD is a co-founder and Managing Partner at Vensana Capital, a leading venture capital fund focused on medical technology. Justin was previously a partner and leader of medical technology investing at NEA, financing many successful cardiovascular device companies, and held positions in strategy, finance and operations in Duke Univ. Health System as it built one of the nation’s first integrated healthcare delivery systems.

Dr. Roxana Mehran is an internationally renowned interventional cardiologist, and clinical research expert. She is Mount Sinai Professor in Cardiovascular Clinical Research and Outcomes; Professor of Medicine (Cardiology) and Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai. Dr Mehran serves on the American College of Cardiology (ACC) Board of Trustees and is a founder and Chief Scientific Officer of the Cardiovascular Research Foundation (CRF). Dr Mehran is currently leading the Lancet Commission on Women’s Cardiovascular Diseases.

Jack Springer has served in senior operating positions at Cordis/Johnson and Johnson, and Medtronic/Invatec, along with being a board member and consultant to several other cardiovascular device companies, including a leading medical device contract research organization. He currently is CEO of Nectero Medical, Executive Chairman of R3 Vascular, and a managing director of RM Global.

Broker-dealer services are provided through Beech Hill Securities ( ), Inc., a FINRA/SIPC member.